ストックスクリーナーアプリを入手
55.50
7.23%
3.74
前日終値:
$51.76
開ける：
$51.03
24時間の取引高:
35.35M
Relative Volume:
1.02
時価総額：
$12.08B
収益：
$1.78B
当期純損益:
$164.40M
株価収益率:
80.43
EPS:
0.69
ネットキャッシュフロー:
$236.51M
1週間 パフォーマンス:
+14.65%
1か月 パフォーマンス:
+15.72%
6か月 パフォーマンス:
+63.57%
1年 パフォーマンス:
+250.82%
1日の値動き範囲:
$50.25
$55.93
1週間の範囲:
$47.48
$55.93
52週間の値動き範囲:
$15.73
$72.98
Hims Hers Health Inc Stock (HIMS) Company Profile
名前
Hims Hers Health Inc
電話
415-851-0195
住所
2269 CHESTNUT ST, SAN FRANCISCO
HIMS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
55.50 | 10.80B | 1.78B | 164.40M | 236.51M | 0.69 |
|
PG
Procter Gamble Co
|
157.90 | 368.28B | 84.28B | 16.07B | 14.05B | 6.51 |
|
UL
Unilever Plc Adr
|
62.89 | 153.93B | 64.99B | 6.71B | 6.53B | 2.4495 |
|
CL
Colgate Palmolive Co
|
83.28 | 67.24B | 20.00B | 3.05B | 3.37B | 3.56 |
|
KMB
Kimberly Clark Corp
|
127.99 | 42.47B | 18.88B | 2.38B | 2.10B | 7.26 |
|
KVUE
Kenvue Inc
|
18.99 | 35.45B | 15.14B | 1.42B | 1.63B | 0.74 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-23 | ダウングレード | Needham | Buy → Hold |
| 2025-06-04 | 繰り返されました | Needham | Buy |
| 2025-04-29 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-02-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | ダウングレード | Citigroup | Neutral → Sell |
| 2025-01-07 | 開始されました | BTIG Research | Buy |
| 2024-12-17 | 開始されました | Morgan Stanley | Overweight |
| 2024-11-14 | ダウングレード | BofA Securities | Buy → Underperform |
| 2024-08-22 | 開始されました | Needham | Buy |
| 2024-08-09 | ダウングレード | Imperial Capital | Outperform → In-line |
| 2024-05-22 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-04-16 | ダウングレード | Jefferies | Buy → Hold |
| 2024-04-10 | 開始されました | Canaccord Genuity | Buy |
| 2024-02-28 | アップグレード | Imperial Capital | In-line → Outperform |
| 2024-02-26 | 開始されました | Leerink Partners | Market Perform |
| 2023-12-07 | 開始されました | Imperial Capital | In-line |
| 2023-07-28 | 開始されました | TD Cowen | Outperform |
| 2023-04-11 | 開始されました | Robert W. Baird | Neutral |
| 2023-02-09 | アップグレード | Jefferies | Hold → Buy |
| 2022-11-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-11-08 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | 開始されました | Truist | Hold |
| 2022-07-15 | 開始されました | SVB Leerink | Underperform |
| 2022-04-14 | 開始されました | Guggenheim | Buy |
| 2022-04-01 | 再開されました | Credit Suisse | Outperform |
| 2022-03-10 | 開始されました | Deutsche Bank | Hold |
| 2021-12-02 | 開始されました | Jefferies | Hold |
| 2021-11-11 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | 開始されました | BofA Securities | Neutral |
| 2021-05-20 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | 開始されました | Truist | Hold |
| 2021-03-09 | 開始されました | Credit Suisse | Neutral |
| 2021-03-02 | アップグレード | Citigroup | Neutral → Buy |
| 2021-02-17 | 開始されました | Citigroup | Neutral |
| 2021-02-12 | 開始されました | Piper Sandler | Neutral |
| 2021-02-08 | 開始されました | Tigress Financial | Buy |
すべてを表示
Hims Hers Health Inc (HIMS) 最新ニュース
Can Hims & Hers Health (HIMS) Redefine Its Growth Story With a New Focus on Hormone Health? - ca.finance.yahoo.com
US FDA chief says Super Bowl ad by Hims & Hers ‘breached’ drug promotion rules - 104.1 WIKY
Hims & Hers Faces FDA Heat As Commissioner Martin Makary Calls Out Super Bowl Ad For Hiding Drug Risks - Benzinga
Alliancebernstein L.P. Buys 78,756 Shares of Hims & Hers Health, Inc. $HIMS - MarketBeat
US FDA chief says Hims & Hers Super Bowl ad violated drug promotion rules - Reuters
Trio In The Hot Medical Sector Is Led By This Retail Health Products Leader. Check Out IBD 50, Stock Spotlight Premium Lists. - Investor's Business Daily
US FDA chief says Super Bowl ad by Hims & Hers 'breached' drug promotion rules - Reuters
Hims & Hers Health (NYSE:HIMS) Trading 8.9% HigherWhat's Next? - MarketBeat
Hims & Hers Health (HIMS) Stock Trades Up, Here Is Why - Yahoo Finance
FDA Chief Says Hims’ Weight-Loss Drug Ad Breached Agency’s Rules - Bloomberg Law News
Hims & Hers Health Stock Surge: Analyzing the Growth - StocksToTrade
Healthcare Stocks To ConsiderSeptember 11th - MarketBeat
Hims & Hers Health (NYSE:HIMS) Shares Gap UpTime to Buy? - MarketBeat
Hims & Hers Surges 64.1% in 6 Months: How to Play the Stock? - Yahoo Finance
Hims and Hers stock maintains Buy rating at BTIG despite GLP-1 slowdown - Investing.com
Scientech Research LLC Sells 8,163 Shares of Hims & Hers Health, Inc. $HIMS - MarketBeat
Investigation announced for Investors in shares of Hims & Hers Health, Inc. (NYSE: HIMS) over potential Wrongdoing - openPR.com
Notable Thursday Option Activity: HIMS, GRMN, EVC - Nasdaq
Hims & Hers Health, Inc. | 9/11/25 - ktnv.com
Hims expands into testosterone treatments - Sherwood News
Sustainable Weight Loss: Personalized Care with Hims & Hers - KNWA FOX24
Hims & Hers Looks Like Hyper Growth At A Reasonable Price (NYSE:HIMS) - Seeking Alpha
Best Medical Stocks Worth WatchingSeptember 9th - MarketBeat
Him and Her’s Health, Inc talks with Nicole DeCosta - KOIN.com
Hims & Hers Stock Rises After Company Launches Treatment Plans For Low Testosterone - Stocktwits
Why Hims & Hers Health (HIMS) Stock Is Trading Up Today - Yahoo Finance
Hims & Hers Stock Jumps On Long-Awaited Foray Into Testosterone - Inkl
Hims & Hers Bets On Hormonal Health To Revive Investor ConfidenceHims & Hers Health (NYSE:HIMS) - Benzinga
Noteworthy ETF Outflows: VTWO, HIMS, FLR, IONQ - Nasdaq
Hims & Hers launches treatment plans for low testosterone - Reuters
Hims to Launch New Offerings for Men With Low Testosterone - Bloomberg.com
Hims & Hers: The Next Chapter For Investors - Seeking Alpha
Hims & Hers to launch new offerings for treating low testosterone in men - Seeking Alpha
The New Standard in Testosterone Treatment: Exclusive Branded Oral Testosterone and Expanded Treatment Options - Hims & Hers Newsroom
Hims expands into hormone health with men’s testosterone treatment - Endpoints News
Hims Launches New Category in Men’s Health with Exclusive Branded Oral Testosterone and Expanded Personalized Treatments - Hims Investor Relations
Hims & Hers Health Expands Testosterone Offerings - The Wall Street Journal
Trump administration moves to regulate pharmaceutical ads on TV and social media (HIMS:NYSE) - Seeking Alpha
Trump aims to curb direct-to-consumer ads for drugs. Hims & Hers Health could be targeted. - MarketWatch
Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
Hims & Hers To Launch Low Testosterone Treatments for Men As Weight-Loss Drug Sales Slow - Stocktwits
Hims & Hers Health (NYSE:HIMS) Shares Down 2.4%What's Next? - MarketBeat
27,889 Shares in Hims & Hers Health, Inc. $HIMS Purchased by Vident Advisory LLC - MarketBeat
Hims & Hers Expanding Partnerships to Build a Global Health Ecosystem - Yahoo Finance
Ohio to tighten oversight of weight-loss copies by limiting inventory - Reuters
Hims & Hers Health (NYSE:HIMS) Rallies 14% This Week, Taking Three-year Gains to 625% - 富途牛牛
Ieq Capital LLC Has $1.70 Million Holdings in Hims & Hers Health, Inc. $HIMS - MarketBeat
Hims & Hers Health, Inc. $HIMS Shares Sold by Comerica Bank - MarketBeat
Hers Health Inc. is moving todayNew Guidance & Accurate Buy Signal Notifications - Newser
Hims & Hers Health Stock Surges Amid Expansion - TipRanks
Nomura Holdings Inc. Purchases 52,042 Shares of Hims & Hers Health, Inc. $HIMS - MarketBeat
Hims Hers Health Inc (HIMS) 財務データ
収益
当期純利益
現金流量
EPS
0.72%
0.74%
大文字化:
|
ボリューム (24 時間):